June 12 – 17, 2022
The Coalition for Epidemic Preparedness Innovations’ ‘100-day mission’ aspires to launch of a new vaccine within 100 days of pathogen identification. We have previously reported a simple fed batch process and strategy of internationally-distributed manufacturing, which enabled 2 billion doses of the ‘Oxford / AstraZeneca’ adenovirus-vectored COVID-19 vaccine to be produced in less than 600 days from publication of the SARS-CoV-2 genome sequence. The majority was made and used in low and middle income countries. Here, after briefly reviewing that previous work, we will describe efforts to further improve adenovirus manufacturing for response to future pathogen outbreaks and variants.
Please click Download on the upper right corner to see the full abstract.
Please click Additional File below for the presentation.
Sandy Douglas, Alexander D Douglas, Carina C D Joe, Rameswara R Segireddy, Adam Berg, Yuanyuan Li, Dimitrio Doultsinos, Cathy Oliveira, Asma Ahmad, Nitin Chopra, Steffi Scholze, Piergiuseppe Nestola, and Julia Niemann, "Accelerating and intensifying manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 days" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/23